Literature DB >> 17553001

Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains.

Elisabet Reyes-Irisarri1, Marjanne Markerink-Van Ittersum, Guadalupe Mengod, Jan de Vente.   

Abstract

We studied the mRNA expression of cGMP-hydrolysing phosphodiesterases (PDEs) in selected brain areas of normal elderly people and patients with Alzheimer's disease. Using radioactive in-situ hybridization histochemistry we found a widespread distribution of the mRNA for PDE2 and PDE9, whereas no specific hybridization signal was observed for PDE5. We observed PDE2 and PDE9 mRNA in all cortical areas studied (insular cortex, entorhinal cortex and visual cortex), although to a different extent. PDE2 mRNA was high in the claustrum, whereas PDE9 mRNA was moderate. PDE2 and PDE9 mRNAs was present in the putamen. No cGMP-hydrolysing PDE expression was observed in the globus pallidus. PDE2 and PDE9 mRNA was observed in all subareas of the hippocampus; however, there were significant differences in the amount of expression. In the Purkinje and cerebellar granule cells only PDE9 expression was observed. PDE2 and PDE9 mRNA expression was not significantly different in Alzheimer's disease brains.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553001     DOI: 10.1111/j.1460-9568.2007.05589.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  27 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  The Phosphodiesterase 9 Inhibitor PF-04449613 Promotes Dendritic Spine Formation and Performance Improvement after Motor Learning.

Authors:  Baoling Lai; Miao Li; Wanling Hu; Wei Li; Wen-Biao Gan
Journal:  Dev Neurobiol       Date:  2018-07-18       Impact factor: 3.964

Review 3.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

4.  Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses.

Authors:  G Aleph Prieto; Brian H Trieu; Cindy T Dang; Tina Bilousova; Karen H Gylys; Nicole C Berchtold; Gary Lynch; Carl W Cotman
Journal:  J Neurosci       Date:  2016-12-16       Impact factor: 6.167

Review 5.  Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease.

Authors:  Katarzyna Urszula Domek-Łopacińska; Joanna B Strosznajder
Journal:  Mol Neurobiol       Date:  2010-03-09       Impact factor: 5.590

Review 6.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

7.  Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice.

Authors:  Anbrin Masood; Ahmed Nadeem; S Jamal Mustafa; James M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  2008-05-02       Impact factor: 4.030

8.  In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.

Authors:  John P Redrobe; Morten Jørgensen; Claus T Christoffersen; Liliana P Montezinho; Jesper F Bastlund; Martin Carnerup; Christoffer Bundgaard; Linda Lerdrup; Niels Plath
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

9.  Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.

Authors:  Camila Bononi Almeida; Christoph Scheiermann; Jung-Eun Jang; Colette Prophete; Fernando Ferreira Costa; Nicola Conran; Paul S Frenette
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.